Amylyx Pharmaceuticals, Inc. (AMLX) financials

Amylyx Pharmaceuticals, Inc. (AMLX) revenue, EBIT and EBITDA, earnings per share, free cash flow, margins, debt and shareholders equity — annual and quarterly history, charted from SEC filings. No account needed.

In fiscal 2025, Amylyx Pharmaceuticals, Inc. reported revenue of $0, down 100.0% year over year, net income of -$145M, diluted EPS of -$1.53 and free cash flow of -$123M.

Revenue (fiscal 2025)

$0

Revenue growth (fiscal 2025)

-100.0%

Net income (fiscal 2025)

-$145M

Diluted EPS (fiscal 2025)

-$1.53

Free cash flow (fiscal 2025)

-$123M

Amylyx Pharmaceuticals, Inc. files with the U.S. Securities and Exchange Commission under CIK 0001658551, classified as Pharmaceutical Preparations.

Explore annual and quarterly revenue, earnings, cash flow, margins, debt and equity from SEC filings.